VKTX: Viking Therapeutics, Inc. Stock

by  •  • Comments Off on VKTX: Viking Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 2,649.05
Enterprise Value ($M) 2,622.37
Book Value ($M) 880.28
Book Value / Share 7.84
Price / Book 3.01
NCAV ($M) 879.17
NCAV / Share 7.83
Price / NCAV 3.01

Profitability (mra)
Return on Invested Capital (ROIC) -0.12
Return on Assets (ROA) -0.11
Return on Equity (ROE) -0.12

Liquidity (mrq)
Quick Ratio 33.09
Current Ratio 33.09

Balance Sheet (mrq) ($M)
Current Assets 907.22
Assets 908.32
Liabilities 28.04
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -150.92
Net Income -109.96
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -87.79
Cash from Investing -553.37
Cash from Financing 612.46

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-04 13G BlackRock, Inc. 5.30 7.48
11-14 13G/A Viking Global Investors Lp 0.60 -85.97
11-12 13G/A Vanguard Group Inc 9.17 0.00
10-18 13G/A State Street Corp 4.20 -18.61

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-02-26 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One)
2024-10-23 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-07-24 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-04-25 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-17 917,505 4,396,118 20.87
2025-04-16 916,465 2,909,455 31.50
2025-04-15 945,840 3,452,157 27.40
2025-04-14 2,048,998 7,838,485 26.14

(click for more detail)

Similar Companies
UPC – Universe Pharmaceuticals INC UPXI – Upexi, Inc.
VERU – Veru Inc. VSTM – Verastem, Inc.
VTGN – Vistagen Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io